SUBSCRIBE
SUBSCRIBE
News   Drug Development

Bayer HealthCare Pharmaceuticals Presents Florbetaben Phase II Study Results at World Congress of Neurology

October 30, 2009 | 
1 min read
BANGKOK, Oct. 30 /PRNewswire/ -- Bayer HealthCare presented results from a global Phase II study of florbetaben, its imaging agent in development for the detection of cerebral beta-Amyloid plaques, at the 19th World Congress of Neurology (WCN).
Clinical research Phase 2 Asia
MORE ON THIS TOPIC
Microscope icon. Molecule and communication background. Connected lines with dots.
Deals
Novartis bets up to $900M for radioligand therapy from China’s BoomRay
September 23, 2026
 · 
2 min read
 · 
Tristan Manalac
Close up shot red darts arrows in the target center on dark blue sky background. Business target or goal success and winner concept.
ALS
Ionis-Otsuka offer ‘groundbreaking’ improvement in function and survival for genetic type of ALS
September 23, 2026
 · 
4 min read
 · 
Heather McKenzie
FDA
Novo’s turnaround plan, weight loss wins, Ultragenyx’s Sanfilippo approval, IPO blitz
September 23, 2026
 · 
2 min read
 · 
Jef Akst
Illustration showing businessman trying to create his own road
FDA
Compass vows to press on with FDA application despite new trial request
September 22, 2026
 · 
3 min read
 · 
Annalee Armstrong